Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.7 EUR | -2.09% | -2.50% | -8.24% |
Mar. 14 | Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 | CI |
Mar. 14 | Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024 |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.24% | 356M | - | ||
+27.92% | 659B | C+ | ||
+27.68% | 557B | B | ||
-4.59% | 359B | C+ | ||
+16.38% | 322B | B- | ||
+9.39% | 297B | C+ | ||
+6.30% | 215B | B+ | ||
+4.80% | 210B | B- | ||
-6.05% | 200B | A+ | ||
-8.58% | 149B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HYL Stock
- Ratings Hyloris Pharmaceuticals SA